Gastroenterology

Rapt Therapeutics files for IPO at $75M Rapt Therapeutics, based in the US, filed to raise to $75 million in its IPO. This had come after five months when the company had retitled itself, which was earlier known as Flx Bio and after three months, it had filed its initial S-1 form with the hope to gain $86 million in its Nasdaq debut. Bristol-Myers Squibb bought Flexus Biosciences and then Rapt was founded in 2015. The company will utilize the takings to get FLX475, a CCR4 antagonist for the cancer treatment, and RPT193, a second CCR4 med, through phase 1 in atopic dermatitis. The capital will also bolster the development of its early-stage inhibitor of general c...